DEXAMETHASONE USE IN MANAGEMENT OF COVID19: A REVIEW

Authors

  • Samer Mohammed College of Pharmacy , University of Baghdad

DOI:

https://doi.org/10.37557/gjphm.v3i1.72

Keywords:

COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomized controlled trial, Steroids, pandemic.

Abstract

The lack of active 2019 coronavirus disease (COVID-19) pandemic treatment creates a challenge for researchers and scientists to find the most appropriate treatment for this disease. Dexamethasone, according to the findings of the RECOVERY clinical trial, declared mid-June 2020 in print media was one of those therapies. Although the results from retrospective studies are not strongly supportive of corticosteroid routine use in COVID-19 despite the signals for some benefits, the dedicated RECOVERY trial found a significant reduction in death with dexamethasone only in severe cases on a ventilator or moderate cases on supplemental oxygen therapy nevertheless, no benefit observed in mild to moderate cases requiring no oxygen. More studies are still necessary to substantiate conclusive use with dexamethasone in COVID-19. This narrative review attempts to summarize all available shreds of evidence from previously published research articles on the use of dexamethasone in COVID-19 pandemic treatment.

Downloads

Download data is not yet available.

Downloads

Published

2021-03-01

How to Cite

Mohammed, S. (2021). DEXAMETHASONE USE IN MANAGEMENT OF COVID19: A REVIEW. Global Journal of Public Health Medicine, 3(1), 279–288. https://doi.org/10.37557/gjphm.v3i1.72

Issue

Section

Review Articles

Similar Articles

You may also start an advanced similarity search for this article.